✉news HealthMedicine first seen 2 d ago, last 2 d ago, peak #37
Proteomic Aging Clocks Enter Clinical Trials
Original: Proteomic Aging Clocks Enter Clinical Trials: What Sponsors Need to Know Before the FDA Does
Proteomic aging clocks — blood-based protein signatures used to estimate biological age — are moving into clinical trials for the first time, raising questions about how regulators, including the US FDA, will evaluate them. Industry commentary is urging trial sponsors to understand validation requirements, biomarker standards and regulatory expectations now, before formal FDA guidance on aging biomarkers exists.
Why now: Sponsors and researchers are weighing how to design and validate trials using biological aging measures ahead of any FDA regulatory framework.
FDAproteomic aging clocksclinical trial sponsors
Rank over time, top of the chart is #1. 2 snapshots from 2 d ago to 2 d ago.
Evidence
- Proteomic Aging Clocks Enter Clinical Trials: What Sponsors Need to Know Before the FDA Does · The Clinical Trial Vanguard
API: https://socialmediatrends-api.osmike.com/v1/trends/2220836